Ï㽶ÊÓƵ

Neil Cross

  1. About us
  2. Our people
  3. Staff profiles
  4. Neil Cross

Dr Neil Cross BSc, PgCert LTHE, FHEA, PhD

Associate Professor in Cancer Biology and Course Leader BSC (Hons) Biomedicine and Health Science

Summary

Dr Neil Cross is an Associate Professor in Cancer Biology at Ï㽶ÊÓƵ. He completed a BSc in Biomedical Chemistry at Ï㽶ÊÓƵ prior to undertaking a PhD and several post-doctoral research positions in cancer biology at The University of Sheffield.

Neil is course leader for BSc (Hons) Biomedicine and Health Science and teaches aspects of molecular biology and cellular biology particularly in relation to a disease mechanisms context.

His research interests are interdisciplinary projects focussed on cancer biology, and he uses this research to inform his teaching.

Neil Cross

Teaching

School of Biosciences and Chemistry

College of Health, Wellbeing and Life Sciences

Course leader for BSc Biomedicine and Health Science

Neil is module leader for final year Advanced Therapeutics and Personalised Medicine and contributes to teaching at all levels of undergraduate teaching including 1st year Human Reproduction and Endocrinology, 1st Year Epidemiology and Public Health, 2nd year Molecular and Cellular Biochemistry, 3rd year Cell Pathology and Infection, Advanced Genetics, and Human Nutrition and Health modules.

At post-graduate level, he is module leader for Therapeutic Targeting in Cancer and teaches across the MSc Cancer Biology programme. He also supervises research projects at undergraduate and post-graduate level.

Courses taught:

  • BSc (Hons) Biomedicine and Health Science
  • BSc (Hons) Biomedical Science
  • BSc (Hons) Biochemistry
  • BSc (Hons) Biology
  • MSc Cancer Biology

Modules taught:

  • L4 Human Reproduction and Endocrinology
  • L4 Epidemiology and Public Health
  • L5 Molecular and Cellular Biochemistry
  • L5 Physiology of Health and Disease
  • L6 Cellular Pathology and Infection
  • L6 Advanced Therapeutics and Personalised Medicine
  • L6 Human Nutrition and Health
  • L6 Advanced Genetics
  • L7 Therapeutic Targeting in Cancer
  • L7 Translational Ï㽶ÊÓƵ

Ï㽶ÊÓƵ

1) 3D cell culture models

Recent studies funded by NC3Rs, Innovate UK, Cancer Ï㽶ÊÓƵ UK and the Marie Sklodowska-Curie Doctoral Training Alliance programme have focused on the development of in vitro alternatives to animal testing of chemotherapy, targeted therapy and radiotherapy using 3D cell culture models. These 3D tumour spheroids mimic many of the biochemical features of tumours such as hypoxia, attenuated drug delivery and low glucose and growth factor levels. Previous work for NC3Rs focused on performing MALDI Mass Spectrometry imaging of small molecules and drugs in these 3D cultures from both cancer, and artificial skin models. Work funded by Innovate UK in collaboration with Asterand Inc. involved developing improved in vitro testing methodologies which may replace patient-derived xenograft/animal testing, by culturing primary human cancer cells in 3D cell culture, allowing drug sensitivity testing to be performed on tumour tissue. Related studies are studying metabolites, and glycomic signatures in 3D cultures of Uveal melanoma. These studies are in collaboration with Dr Laura Cole at SHU. Other related work with Prof Judy Coulson and  is investigating the potential for using volatile organic metabolites in the diagnosis of mesothelioma, and assessing the source of these in 3D cell culture modules.

2) Enhancement of apoptotic and ferroptotic programmed cell death

Recent studies have focused on how tumours evade apoptotic signals from Tumour Necrosis Factor (TNF) superfamily members, with particular emphasis on the potential anti-tumour agent TRAIL (TNF-Related Apoptosis Inducing Ligand). Current studies are focusing on mechanisms of TRAIL resistance in cancer cells, and whether combinations of agents such as histone deactylase (HDAC) inhibitors, nuclear export inhibitors and proteasome inhibitors can reverse TRAIL resistance. In our recent studies, we have also demonstrated that both Histone methytransferases and nuclear export inhibitors in particular can potently enhance tumour cell sensitivity to TRAIL in a range of tumour cells, and that these effects are more potent in 3D cell culture. More recent work has examined the role of ferroptosis in mediating resistance to both chemotherapy and radiotherapy in breast cancer 3D cell cultures.

3) Targeted Gold nanoparticle-mediated radio-sensitisation of tumour cells

The mitochondria are a potential target for anti-tumour agents due to a) their central role in energy dependency and b) their role in regulating apoptosis. Cancer cells have an increased mitochondrial membrane potential vs. normal cells, allowing their selective targeting by lipophilic cations. We have used phosphonium-based conjugation to allow targeting of molecules to the mitochondrion, initially focusing on gold nanoparticles as a cargo. We have shown that these nanoparticles enhance both photothermal therapy responses, and more recently, radiotherapy responses, and our very recent work has extended these studies to nuclear-targeted nanoparticles using nuclear localisation signal peptides.  This work is in collaboration with Prof. Neil Bricklebank at Ï㽶ÊÓƵ.

Current research is focussed into four key areas:

  • The development of in vitro alternatives to animal testing of chemotherapy, targeted therapy and radiotherapy using 3D cell culture models 
  • The assessment of metabolomics in 3D cell cultures by mass spectrometry imaging
  • Identification of novel biomarkers useful for stratification of cancer therapies
  • Development of novel cancer therapeutics, and overcoming drug resistance

Collaborators

  • Dr Helen Kalirai and Dr Karen Aughton at University of Liverpool
  • Prof Judy Coulson at University of Liverpool
  • Dr Ning Wang at University of Leicester
  • Dr Jennifer Munkley at University of Newcastle
  • Dr Lewis Quayle at Ï㽶ÊÓƵ
  • Dr Laura Cole at Ï㽶ÊÓƵ
  • Dr Sarah Haywood-Small at Ï㽶ÊÓƵ
  • Dr Alice Johnson at Ï㽶ÊÓƵ
  • Prof Neil Bricklebank at Ï㽶ÊÓƵ

Funding

  • Cancer Ï㽶ÊÓƵ UK
  • Marie Sklodowska-Curie Doctoral Training Alliance programme
  • Innovate UK
  • National Centre for Reduction, Refinement and Replacement of Animals in Ï㽶ÊÓƵ (Nc3Rs)
  • Yorkshire Cancer Ï㽶ÊÓƵ
  • Bone Cancer Ï㽶ÊÓƵ Trust
  • Weston Park Hospital Cancer Appeal
 

Publications

Journal articles

Little, L.D., Barnett, S.E., Issitt, T., Bonsall, S., Carolan, V., Allen, E., ... Haywood-Small, S. (2024). . Journal of breath research, 18 (4).

Pearce, S., Cross, N.A., Smith, D.P., Clench, M., Flint, L.E., Hamm, G., ... Cole, L. (2024). . Metabolites, 14 (6).

Knowles, A.A., Campbell, S.G., Cross, N.A., & Stafford, P. (2023). . Microorganisms, 11 (3).

Hudson, K., Cross, N.A., Jordan-Mahy, N., & Leyland, R. (2022). Programmed death-ligand 1 expression in human cancer three-dimensional cell culture models. .

Mahbub, A.A., Le Maitre, C., Cross, N., & Jordan-Mahy, N. (2022). . Scientific Reports, 12 (1).

Flint, L.E., Hamm, G., Ready, J.D., Ling, S., Duckett, C.J., Cross, N.A., ... Clench, M.R. (2021). . Metabolites, 11 (8).

Arhoma, A., Southan, J., Chantry, A.D., Haywood-Small, S.L., & Cross, N.A. (2021). EZH2 inhibition enhances TRAIL responses in multiple myeloma but not in quiescent cells. BioRxiv.

Knowles, A., Campbell, S., Cross, N., & Stafford, P. (2021). . Frontiers in Microbiology, 12.

Spencer, C.E., Flint, L.E., Duckett, C., Cole, L., Cross, N., Smith, D., & Clench, M. (2021). . Expert Review of Proteomics, 17 (11-12), 827-841.

Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020). . Frontiers in Immunology, 11, 568931.

Flint, L.E., Hamm, G., Ready, J.D., Ling, S., Duckett, C.J., Cross, N.A., ... Clench, M.R. (2020). . Analytical Chemistry.

PalubeckaitÄ—, I., Crooks, L., Smith, D., Cole, L., Bram, H., Le Maitre, C., ... Cross, N.A. (2019). . Journal of Mass Spectrometry.

Phillips, K., Wright, N., McDermott, E., & Cross, N. (2019). . Biochemical and Biophysical Ï㽶ÊÓƵ Communications, 517 (2), 383-389.

Mahbub, A.A., Le Maitre, C., Haywood-Small, S., Cross, N., & Jordan-Mahy, N. (2019). . Oncotarget, 10 (44).

Lalwani, N., Allen, D., Horton, P.N., Coles, S.J., Cross, N., & Bricklebank, N. (2019). . Polyhedron, 158, 515-523.

Doherty, R.E., Sisley, K., Hammond, D.W., Rennie, I.G., & Cross, N. (2017). . Investigative Opthalmology & Visual Science, 58 (12), 5387.

Arhoma, A., Chantry, A.D., Haywood-Small, S., & Cross, N. (2017). . Experimental cell research.

Mahbub, A., Le Maitre, C., Haywood-Small, S., Cross, N., & Jordan-Mahy, N. (2017). . Oncotarget, 8 (62), 104877-104893.

Chen, Y.-.S., Allen, D., Cross, N.A., Pitak, M.B., Tizzard, G.J., Coles, S.J., & Bricklebank, N. (2017). . European Journal of Medicinal Chemistry, 125, 528-537.

Khalid, H. (2016). PAD4 inhibitors: potential sensitizers of tumour cells to TRAIL-induced apoptosis. Bioscience Horizons, 9, hzw003.

Harvey, A., Day, R., Cole, L.M., Bartlett, M., Warwick, J., Bojar, R., ... Clench, M.R. (2016). . Proteomics, 16 (11-12), 1718-1725.

Lalwani, N., Chen, Y.-.S., Brooke, G., Cross, N.A., Allen, D.W., Reynolds, A., ... Bricklebank, N. (2015). . Chemical Communications, 51 (19), 4109-4111.

Mahbub, A.A., Le Maitre, C.L., Haywood-Small, S.L., Cross, N.A., & Jordan-Mahy, N. (2015). . Cell Death and Disease, 6, e2028.

Mahbub, A.A., Le Maitre, C.L., Haywood-Small, S.L., Cross, N.A., & Jordan-Mahy, N. (2015). . Cell Death Discovery, 1 (15043), 1-12.

Zaini, R., Haywood-Small, S., Cross, N., & Le Maitre, C. (2015). . Journal of Blood Disorders and Transfusion, 6 (2).

Mahbub, A.A., Le Maitre, C., Haywood-Small, S., McDougall, G.J., Cross, N., & Jordan-Mahy, N. (2013). . Anti-cancer agents in medicinal chemistry, 13 (10), 1601-1613.

Hsu, Y.P., Staton, C.A., Cross, N., & Buttle, D.J. (2012). . International Journal Of Experimental Pathology, 93 (1), 70-77.

Ju-Nam, Y., Chen, Y.-.S., Ojeda, J.J., Allen, D.W., Cross, N.A., Gardiner, P.H.E., & Bricklebank, N. (2012). . RSC Advances, 2 (27), 10345-10351.

Singh Mudhar, H.S., Scott, I., Ul-Hassan, A., Burton, D., Doherty, R., Cross, N., ... Sisley, K. (2012). . Histopathology, 61 (4), 751-754.

Doherty, R.E., Haywood-Small, S.L., Sisley, K., & Cross, N.A. (2011). . Biochemical and Biophysical Ï㽶ÊÓƵ Communications, 414 (4), 801-807.

Sisley, K., Doherty, R., & Cross, N. (2011). . British Journal of Ophthalmology, 95 (5), 620-623.

Muthana, M., Giannoudis, A., Scott, S.D., Fang, H.-.Y., Coffelt, S.B., Morrow, F.J., ... Maitland, N.J. (2011). . Cancer Ï㽶ÊÓƵ, 71, 1805-1815.

Kokab, A., Jennings, R., Eley, A., Pacey, A.A., & Cross, N.A. (2010). . Microbial Pathogenesis, 49 (5), 217-225.

Guzmán-Ramírez, N., Völler, M., Wetterwald, A., Germann, M., Cross, N.A., Rentsch, C.A., ... Cecchini, M.G. (2009). . The Prostate, 69 (15), 1683-1693.

Al-Mously, N., Cross, N.A., Eley, A., & Pacey, A.A. (2009). . Fertility and sterility, 92 (5), 1606-1615.

Cross, N., Waterman, E.A., Jokonya, N., Fowles, A., Buckle, C.H., Phillips, J., ... Eaton, C.L. (2008). . Journal of cellular biochemistry, 104 (4), 1452-1464.

Cross, N.A., Fowles, A., Reeves, K., Jokonya, N., Linton, K., Holen, I., ... Eaton, C.L. (2008). . The Prostate, 68 (15), 1707-1714.

Tozer, G.M., Akerman, S., Cross, N.A., Barber, P.R., Bjorndahl, M.A., Greco, O., ... Kanthou, C. (2008). . Cancer research, 68 (7), 2301-2311.

Waterman, E.A., Cross, N.A., Lippitt, J.M., Cross, S.S., Rehman, I., Holen, I., ... Eaton, C.L. (2007). The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers. International journal of cancer, 121 (9), 1958-1966.

Cross, N.A., Papageorgiou, M., & Eaton, C.L. (2007). . Biochemical Society Transactions, 35 (Pt 4), 698-700.

Bryant, R.J., Cross, N.A., Eaton, C.L., Hamdy, F.C., & Cunliffe, V.T. (2007). . The Prostate, 67 (5), 547-556.

Cross, N.A., Reid, S.V., Harvey, A.J., Jokonya, N., & Eaton, C.L. (2006). . Growth Factors, 24 (4), 233-241.

Cross, N.A., Ganesh, A., Parpia, M., Murray, A.K., Rennie, I.G., & Sisley, K. (2006). . Eye, 20 (4), 476-81.

Holen, I., Cross, S.S., Neville-Webbe, H.L., Cross, N.A., Balasubramanian, S.P., Croucher, P.I., ... Eaton, C.L. (2005). Breast Cancer Ï㽶ÊÓƵ and Treatment, 92 (3), 207-15.

Cross, N.A., Chandrasekharan, S., Jokonya, N., Fowles, A., Hamdy, F.C., Buttle, D.J., & Eaton, C.L. (2005). . The Prostate, 63 (3), 269-75.

Cross, N.A., Rennie, I.G., Murray, A.K., & Sisley, K. (2005). . Clinical & Experimental Metastasis, 22 (2), 107-113.

Nyambo, R., Cross, N., Lippitt, J., Holen, I., Bryden, G., Hamdy, F.C., & Eaton, C.L. (2004). . Journal of Bone and Mineral Ï㽶ÊÓƵ (JBMR), 19 (10), 1712-1721.

Neville-Webbe, H.L., Cross, N.A., Eaton, C.L., Nyambo, R., Evans, C.A., Coleman, R.E., & Holen, I. (2004). . Breast Cancer Ï㽶ÊÓƵ and Treatment, 86 (3), 269-279.

Dizeyi, N., Bjartell, A., Nilsson, E., Hansson, J., Gadaleanu, V., Cross, N., & Abrahamsson, P.-.A. (2004). . The Prostate, 59 (3), 328-336.

Cross, N.A., Murray, A.K., Rennie, I.G., Ganesh, A., & Sisley, K. (2003). . Melanoma Ï㽶ÊÓƵ, 13 (5), 435-440.

Woodward, J.K.L., Elshaw, S.R., Murray, A.K., Nichols, C.E., Cross, N., Laws, D., ... Sisley, K. (2002). . Investigative ophthalmology & visual science, 43 (10), 3144-3152.

Elshaw, S.R., Sisley, K., Cross, N., Murray, A.K., MacNeil, S.M., Wagner, M., ... Rennie, I.G. (2001). A comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of alpha1beta1, alpha4beta1 and alpha6beta1 integrins. The British journal of ophthalmology, 85 (6), 732-738.

Cross, N.A., Kellock, D.J., Kinghorn, G.R., Taraktchoglou, M., Bataki, E., Oxley, K.M., ... Eley, A. (1999). . Antimicrobial agents and chemotherapy, 43 (9), 2311-2313.

Conference papers

Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2021). Characterization of 3D models of human breast, prostate and colorectal cancer. CANCER RESEARCH, 81 (13).

Brooks, A.D., Wright, N.E., Xu, Y.-.M., Wijeratne, K., Tewary, P., Cross, N., ... Sayers, T.J. (2018). Abstract 2671: 17beta-hydroxywithanolides inhibit the proliferation of castration-resistant prostate cancer cells by reducing levels of cFLIP. Cancer Ï㽶ÊÓƵ, 78 (13_Supplement), 2671.

Harvey, A.C., Place, G., Baggott, K., Samra, S., Freathy, C., & Cross, N. (2017). Abstract B30: Development of robust in vitro 3D models of human tumors for the identification and evaluation of anti-cancer drugs. Cancer Ï㽶ÊÓƵ, 77 (22_Supplement), B30.

Zaini, R., Small, S.H., Cross, N., & Le Maitre, C. (2015). Combination therapy with Falcarinol on human lymphoid leukaemia cell lines and increase the expression of cytochrome C, Bax and SMAC/Diablo. BRITISH JOURNAL OF HAEMATOLOGY, 169, 72.

Harvey, A., Cole, L., Clench, M., Cross, N., & Smith, D. (2015). MALDI-IMS-MSI for the Analysis of 3D Tissue-Engineered Psoriatic Skin Models. TISSUE ENGINEERING PART A, 21, S163.

Wilson, A., Jordan-Mahy, N., Haywood-Small, S., Cross, N.A., & Le Maitre, C. (2012). Extracts From Red and White Cabbage Contains Bio-Active Compounds Which Induce Apoptosis in Myeloid and Lymphoid Leukaemia Cell Lines. JOURNAL OF PATHOLOGY, 228, S37.

Mahbub, A., Le Maitre, C., Haywood-Small, S.L., McDougall, G., Cross, N.A., & Jordan-Mahy, N. (2012). The Anti-cancerous Potential of Polyphenols in the Treatment of Human Myeloid and Lymphoid Leukaemia. JOURNAL OF PATHOLOGY, 228, S34.

Zaini, R., Haywood, S., Brandt, K., Clench, M.R., Cross, N., & Le Maitre, C. (2012). Synergistic Action of Falcarinol on Induction of Apoptosis on Human Lymphoid Leukaemia Cell Lines. JOURNAL OF PATHOLOGY, 228, S38.

Doherty, R., Hoh, L., Rennie, I., Cross, N., & Sisley, K. (2012). Isolation and characterisation of cancer stem cells in uveal melanoma. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 30, S61.

Doherty, R.E., Hoh, L., Rennie, I., Sisley, K., & Cross, N.A. (2012). Isolation and Characterisation of Cancer Stem Cells in Solid Tumours. JOURNAL OF PATHOLOGY, 228, S34.

Doherty, R., Hoh, L., Rennie, I., Sisley, K., & Cross, N. (2012). 269 Isolation and Characterisation of Cancer Stem Cells in Solid Tumours. European Journal of Cancer, 48, S65-S66.

Adeniji, O.O., Molokwu, C.N., Waterman, E.A., Cross, N.A., Hamdy, F.C., & Buttle, D.J. (2008). TIMP-3 expression is regulated by androgen and TNF in prostate stromal and cancer cells. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 89 (3), A9.

Adeniji, O.O., Molokwu, C.N., Waterman, E.A., Cross, N.A., Hamdy, F.C., & Buttle, D.J. (2007). TIMP-3 expression in prostate stromal and tumour cells is regulated by androgen and TNF. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 88 (6), A93-A94.

Adeniji, O.O., Molokwu, C.N., Waterman, E.A., Cross, N.A., Hamdy, F.C., & Buttle, D.J. (2007). Evaluating the role of ADAMTS proteoglycanases and TIMP-3 in prostate cancer progression. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 88 (4), A58.

Woodward, J.K.L., Lefley, D.V., Cross, N.A., Ottewell, P.D., Battle, D.J., Coleman, R.E., & Holen, I. (2007). Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, 22 (7), 1142-1143.

Woodward, J., Lefley, D., Cross, N., Ottewell, P.D., Buttle, D.J., Coleman, R.E., & Holen, I. (2007). Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 88 (6), A97.

Cross, N.A., Papageorgiou, M., Lippitt, J., Nyambo, R., Hamdy, F.C., & Eaton, C.L. (2007). Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 88 (6), A94.

Phillips, J., Rissanen, M., Cross, N., Proctor, L., Sokhi, D., Vaisanen, V., ... Hamdy, F.C. (2007). 909 QUALITATIVE AND QUANTITATIVE PSAMRNA DETECTION IN PROSTATE CANCER - A USEFUL TOOL FOR THE CLINICIAN? European Urology Supplements, 6 (2), 250.

Bryant, R.J., Cross, N.A., Eaton, C.L., Hamdy, F.C., & Cunliffe, V.T. (2007). 435 THE POLYCOMB GROUP PROTEIN EZH2 IS REQUIRED FOR TRANSCRIPTIONAL REPRESSION OF P21 AND MMP7 IN PROSTATE CANCER CELLS. European Urology Supplements, 6 (2), 131.

Molokwu, C., Waterman, E., Cross, N., Buttle, D.J., Hamdy, F.C., & Eaton, C. (2005). Analysis of the functional role of ADAMTS enzymes in prostate cancer. BJU INTERNATIONAL, 95, 29.

Papageorgiou, M., Lippitt, J., Nyambo, R., Cross, N., Hamdy, F.C., & Eaton, C.L. (2005). Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro. CANCER TREATMENT REVIEWS, 31, S36.

Nyambo, R., Neville-Webbe, H., Holen, I., Cross, N.A., Hamdy, F.C., & Eaton, C.L. (2004). Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis. JOURNAL OF BONE AND MINERAL RESEARCH, 19 (9), 1572.

Chandrasekharan, S., Buttle, D.J., Holen, I., Cross, N.A., & Hamdy, F.C. (2003). Expression pattern of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) proteinases in human prostate cancer celllines. JOURNAL OF UROLOGY, 169 (4), 58.

Nyambo, R., Cross, N.A., Lippit, J., Holen, I., Bryden, A.A.G., & Eaton, C.L. (2003). Human bone marrow stromal cells (hBMSC) protect prostate cancer cells from trail induced apoptosis. BRITISH JOURNAL OF CANCER, 88, S26.

Cross, N., Harvey, A., & Eaton, C.L. (2002). Autocrine activities of transforming growth factor beta 1 in prostatic stromal cells. JOURNAL OF UROLOGY, 167 (4), 220-221.

Book chapters

Sayers, T., & Cross, N.A. (2014). ISBN-13: 9780199676866. In Rees, R.C. (Ed.) Tumour Immunology and Immunotherapy Chapter 8: Triggering death receptors as a means of inducing tumoricidal activity. Oxford University Press

Sayers, T., & Cross, N.A. (2014). ISBN-13: 9780199676866. In Rees, R.C. (Ed.) Tumour Immunology and Immunotherapy Chapter 8: Triggering death receptors as a means of inducing tumoricidal activity. Oxford University Press

Theses / Dissertations

Alzufairi, A.A. (2024). . (Doctoral thesis). Supervised by Cross, N., & Jordan-Mahy, N.

Alzufairi, A. (2024). The Induction of Ferroptosis's in 3D Models of Breast Cancer. (Doctoral thesis). Supervised by Jordan-Mahy, N., & Cross, N.

Knowles, A.A. (2023). . (Doctoral thesis). Supervised by Stafford, P., Campbell, S., & Cross, N.

Hudson, K.V. (2023). . (Doctoral thesis). Supervised by Leyland, R., Cross, N., & Jordan-Mahy, N.

Flint, L.E. (2021). . (Doctoral thesis). Supervised by Clench, M., Cross, N., Cole, L., & Smith, D.

Palubeckaite, I. (2018). . (Doctoral thesis). Supervised by Cross, N.

Arhoma, A.A. (2017). . (Doctoral thesis). Supervised by Cross, N.

Wright, N. (2016). . (Doctoral thesis). Supervised by Cross, N.

Mahbub, A.A.-.H. (2015). . (Doctoral thesis). Supervised by Jordan-Mahy, N., Cross, N., Le Maitre, C., & Haywood-Small, S.

Chen, Y.-.S. (2014). . (Doctoral thesis). Supervised by Bricklebank, N., & Cross, N.

Presentations

Campbell, S., Knowles, A., Cross, N., & Stafford, P. (2022). Porphyromonas gingivalis gingipains modulate host translational control during oxidative stress. Presented at: Microbiology Society annual conference, Belfast

Knowles, A., Campbell, S., Cross, N., & Stafford, P. (2021). Characterising the role of the Integrated Stress Response in the pathomechanism of the periodontopathogen Porphyromonas gingivalis. Presented at: European oral microbiology workshop, Online conference

Knowles, A., Campbell, S., Cross, N., & Stafford, P. (2021). Characterising the role of the Integrated Stress Response in the pathomechanism of the periodontopathogen Porphyromonas gingivalis. Presented at: Oral microbiology and immunology group workshop, Virtual conference

Posters

Knowles, A., Campbell, S., Cross, N., & Stafford, P. (2022). Characterising the role of the Integrated Stress Response in the pathomechanism of the periodontopathogen Porphyromonas gingivalis. Presented at: Translation UK, Ï㽶ÊÓƵ

Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2021). . Presented at: British Society for Immunology Congress 2021, Edinburgh, UK, 2021

Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020). . Presented at: EACR-AACR-ASPIC Conference: Tumour Microenvironment, Lisbon, Portugal, 2020

Hudson, K., Jordan-Mahy, N., Cross, N., & Leyland, R. (2019). . Presented at: BACR: Tumour Microenvironment meeting, Nottingham, UK, 2019

Stokes, H., Cross, N., & Leyland, R. (2018). . Presented at: BMRC/MERI Winter Poster Event 2018, Sheffield, 2018

Hudson, K., Cross, N., Jordan-mahy, N., & Leyland, R. (2018). . Presented at: BMRC/MERI Winter Poster Event, Sheffield, 2018

Dowling, J., Ferriera de Matos, C., Leyland, R., & Cross, N. (2018). . Presented at: British Society for Immunology: Yorkshire Immunology Group Symposium 2018, University of York, UK, 2018

Other activities

Dr Cross has previously been a member of university validation panels, assessing new course provision at course approval events. He is a specialist scientific reviewer for Innovate UK, assessing funding applications on molecular diagnostics and novel cancer therapeutics, and a member of the Sheffield Children's Hospital Special Trustees Scientific Advisory Committee.

Postgraduate supervision

Current doctoral research projects:
  • Georgia Millard. Metabolomic and glycomic landscape of Uveal melanoma. In collaboration with Dr Laura Cole, Dr Helen Kalirai and Dr Karen Aughton
  • Bradley Unwin. Tumour targeting using gold-polyphenol complexes. In collaboration with Dr Alice Johnson
  • Sophie Pearce. Developing novel treatments for refractory and relapsed osteosarcoma using an advanced pre-clinical model. In collaboration with Dr Laura Cole.
  • Ronak Naeemaee. Unlocking Precision Medicine: Advanced Survival Analysis Tools for Cancer Biomarker Validation. In collaboration with Dr Lewis Quayle.
  • Imran Jabber. Modelling a Human Chorionic Gonadotropin (hCG) Immunoassay for Treatment Response in Low-Risk Gestational Trophoblastic Neoplasia (GTN). Director of Studies (in collaboration with Prof Barry Hancock, University of Sheffield). 
 

Previous PhD students:
  • Dr Cristiana Matos. Assessment of gold nanoparticles as radiosensitisers in 3D cell cultures. 
  • Dr Alaa Al-Zufairi. Enhancement of radio- and chemotherapy responses using ferroptosis inducers. 
  • Dr Alex Knowles. Crosstalk between host stress-induced translational control and infection by Porphyromonas gingivalis.
  • Dr Katie Hudson. Evaluating anti-cancer pathways in 2D and 3D cell culture systems. 
  • Dr Lucy Flint. Quantification in MS imaging: quantification of biopharmaceuticals in 3D cell cultures. 
  • Dr Ieva Palubeckaite.  MALDI-MSI determination of protein expression in 3D cell cultures. 
  • Dr Amal Arhoma. Enhancement of Death receptor-mediated apoptosis on Multiple Myeloma.
  • Dr Nikhil Lalwani. Triphenylarsonium-functionalised gold nanoparticles: Potential nanocarriers for intracellular therapeutics.
  • Dr Nicola Wright. Role of cancer stem cells in breast and prostate cancer.
  • Dr Amani Mahbub. The anti-cancer potentials of polyphenols in the treatment of leukaemia.
  • Dr Jenni Chen. Phosphonium-functionalised gold nanoparticles for mitochondrial-targeted therapeutics.
  • Dr Rachel Doherty. The role of Cancer Stem Cells in uveal melanoma.Dr Abas Kokab. The role of Chlamydia trachomatis in male infertility.

Cancel event

Are you sure you want to cancel your place on Saturday 12 November?

Close
}